ADC Development for Solid Tumors

Solid tumors are a widespread type of tumors causing a large number of incidence and mortality in the world. Although traditional therapies are benefit for the patients, they show a poor prognosis for resistant cancer. Currently, immunotherapy especially the antibody-drug conjugate (ADC) has emerged as a new and promising therapeutic option, showing significant survival benefit for solid tumors in multiple disease sites and indications.

Creative Biolabs is a leading service provider in the field of developing breakthrough immunotherapy products for cancers therapy. At present, we offer one-stop ADCs design and construction services targeting solid tumors. Our innovative linker technologies and effective bioconjugation platforms will facilitate your drug discovery and development.

Introduction of Solid Tumors

Solid tumor refers to an abnormal mass of tissue that usually does not form cysts or liquid areas. Solid tumors can be benign (not cancer), or malignant (cancer). Benign tumors are not cancer absolutely. They usually grow slowly and do not have the ability of metastasis to invade adjacent tissue or organs. Benign tumors sometimes disappear without any treatment. However, some benign tumors may modify their behaviour to acquire the capacity to invade and spread, and thus become malignant. Malignant solid tumors belong to the cancerous definitely. If the malignancy occurs in local tissue, it is called "the primary tumour". When the tumour spreads to other sites, it is called metastasis. Different types of solid tumors are named based on the type of cells that form them, such as the sarcomas, carcinomas, and lymphomas.

Solid Tumors. Fig.1 Solid Tumors.

Current Therapeutic Strategies for Solid Tumors

To date, the traditional therapeutic approaches for solid tumors include surgery, chemotherapy, radiation therapy, and hormonal therapy. Nowadays, targeted immunotherapy has become a new standard therapy displaying survival benefit for solid tumors in multiple disease sites and indications.

Immune checkpoint inhibitors represent one of the effective therapy agents for many solid tumour types. For example, Ipilimumab, the first checkpoint inhibitor targeting the CTLA-4 protein, demonstrated a significant survival benefit in metastatic melanoma. Besides, anti-PD-1 antibodies were designed as the next immune checkpoint blocking agents, and showed improve outcomes with less toxicity. Pembrolizumab and Nivolumab are two anti-PD-1 antibodies and have obvious survival benefits in second-line therapy or first-line therapy for melanoma as single agents. In addition, Nivolumab, Pembrolizumab, and Durvalumab have been approved by the FDA for the second-line treatment of urothelial cancer currently.

Chimeric antigen receptors T cells therapy (CAR-T cell) is another promising and potential treatment method for the solid tumors. Currently, CAR-T cells target the FRα and GD2 targets are developed to treat ovarian cancer and neuroblastoma, respectively. Furthermore, a variety of clinical trials of CAR-T cell therapy against different antigens for treating solid tumors are ongoing.

Another outstanding immunotherapy strategy for the solid tumors treatment is ADC. So far, various ADCs have been developed and investigated targeting different markers in solid tumors, for instance, the Tisotumab vedotin (HuMax‑TF‑ADC), HuMax‑Axl‑ADC, MEDI547, PF‑06263507 (also known as ADC 5T4), SAR428926, Cantuzumab mertansine (SB‑408075), CanAg (a novel glycoform of MUC1), IMGN388, U3‑1402II, BMS‑986148, Aprutumab ixadotin (BAY1187982), Telisotuzumab vedotin (also known as ABBV‑399), Enfortumab vedotin (also known as ASG‑22ME), ABBV‑221, LOP 628, DS‑8201aII, Depatuxizumab mafodotin (also known as ABT‑414) and SAR408701. All of these ADCs are assessed in different clinical trials stages and displayed significant antitumor activity.

Tisotumab vedotin mechanism of action. Fig.2 Tisotumab vedotin mechanism of action. (Chenard-Poirier, 2017)

What Can We Do for You?

Creative Biolabs is a biotech company committed to providing clients comprehensive ADC development service. We intend to realize the full potential of your ADCs drug candidates through our first-class technology platforms and mature experience. Now Creative Biolabs provides ADCs preparation services targeting various biomarkers for the solid tumors therapy with its core strength in high quality antibody development, medicinal chemistry and bio-conjugation. At Creative Biolabs, targets of ADC development for solid tumors includes:

If you want to learn more about our ADCs related products and services, please contact us.


  1. Chenard-Poirier, M.; et al. 1184PA phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors. Annals of Oncology. 2017, 28(5).

For Research Use Only. NOT FOR CLINICAL USE.

Online Inquiry
*E-mail Address:
*Products or Services Interested:
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us